PMVP PMV Pharmaceuticals

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Bank of America Healthcare Conference on Thursday, May 13, 2021. The company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Bank of America Healthcare Conference
Date:Thursday, May 13, 2021
Time:12:30 PM ET
Webcast:

A replay of the presentation will be available by visiting the “” section of the PMV Pharmaceuticals website.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.  PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit .

Contact

For Investors & Media:

Winston Kung

Chief Financial Officer



EN
05/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PMV Pharmaceuticals

 PRESS RELEASE

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim...

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a media...

 PRESS RELEASE

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and ...

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis   Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a...

 PRESS RELEASE

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD Cowen 6th Annual Oncology I...

 PRESS RELEASE

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and C...

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for approximately 50 patients with at least 18 weeks of follow-upCash, cash equivalents, and marketable securities of $165.8 million as of March 31, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Ma...

 PRESS RELEASE

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corpo...

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed or refractory A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch